Kimmel Cancer Center researchers find drugs targeting chromosomal instability may fight a particular breast cancer subtype

Kimmel Cancer Center researchers find drugs targeting chromosomal instability may fight a particular breast cancer subtype A team of researchers at Jefferson’s Kimmel Cancer Center has shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). … Continue reading “Kimmel Cancer Center researchers find drugs targeting chromosomal instability may fight a particular breast cancer subtype”

Kimmel Cancer Center researchers find drugs targeting chromosomal instability may fight a particular breast cancer subtype

A team of researchers at Jefferson’s Kimmel Cancer Center has shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression. The researchers used various in vitro and in vivo model systems to show that elevated levels of cyclin D1 promotes CIN and correlate with CIN in the luminal B breast cancer subtype. Cyclin D1 protein is elevated in breast, prostate, lung and gastrointestinal malignancies.

Click here to read the full press release

                                        ###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply